Annual Total Liabilities
$86.30 M
-$78.88 M-47.75%
December 31, 2023
Summary
- As of February 6, 2025, LGND annual total liabilities is $86.30 million, with the most recent change of -$78.88 million (-47.75%) on December 31, 2023.
- During the last 3 years, LGND annual total liabilities has fallen by -$566.46 million (-86.78%).
- LGND annual total liabilities is now -88.14% below its all-time high of $727.68 million, reached on December 31, 2019.
Performance
LGND Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$113.69 M
+$22.48 M+24.65%
September 30, 2024
Summary
- As of February 6, 2025, LGND quarterly total liabilities is $113.69 million, with the most recent change of +$22.48 million (+24.65%) on September 30, 2024.
- Over the past year, LGND quarterly total liabilities has increased by +$12.36 million (+12.20%).
- LGND quarterly total liabilities is now -91.92% below its all-time high of $1.41 billion, reached on September 30, 2018.
Performance
LGND Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
LGND Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -47.8% | +12.2% |
| 3 y3 years | -86.8% | -51.5% |
| 5 y5 years | -87.7% | -51.5% |
LGND Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -81.9% | at low | -76.1% | +31.7% |
| 5 y | 5-year | -88.1% | at low | -84.4% | +31.7% |
| alltime | all time | -88.1% | +323.1% | -91.9% | +1457.4% |
Ligand Pharmaceuticals Incorporated Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $113.69 M(+24.6%) |
| Jun 2024 | - | $91.21 M(-15.0%) |
| Mar 2024 | - | $107.35 M(+24.4%) |
| Dec 2023 | $86.30 M(-47.8%) | $86.30 M(-14.8%) |
| Sep 2023 | - | $101.33 M(+8.7%) |
| Jun 2023 | - | $93.21 M(-43.4%) |
| Mar 2023 | - | $164.76 M(-0.3%) |
| Dec 2022 | $165.18 M(-65.3%) | $165.18 M(-29.5%) |
| Sep 2022 | - | $234.31 M(-14.5%) |
| Jun 2022 | - | $273.92 M(-12.2%) |
| Mar 2022 | - | $311.99 M(-34.5%) |
| Dec 2021 | $476.43 M(-27.0%) | $476.43 M(+3.2%) |
| Sep 2021 | - | $461.59 M(-1.7%) |
| Jun 2021 | - | $469.77 M(-14.5%) |
| Mar 2021 | - | $549.28 M(-15.9%) |
| Dec 2020 | $652.76 M(-10.3%) | $652.76 M(+18.8%) |
| Sep 2020 | - | $549.63 M(+0.3%) |
| Jun 2020 | - | $547.93 M(+4.6%) |
| Mar 2020 | - | $524.02 M(-28.0%) |
| Dec 2019 | $727.68 M(+4.0%) | $727.68 M(+4.4%) |
| Sep 2019 | - | $696.89 M(-8.3%) |
| Jun 2019 | - | $760.38 M(-8.8%) |
| Mar 2019 | - | $834.01 M(+19.2%) |
| Dec 2018 | $699.89 M(+177.3%) | $699.89 M(-50.2%) |
| Sep 2018 | - | $1.41 B(+13.5%) |
| Jun 2018 | - | $1.24 B(+381.0%) |
| Mar 2018 | - | $257.49 M(+2.0%) |
| Dec 2017 | $252.37 M(+9.4%) | $252.37 M(+6.2%) |
| Sep 2017 | - | $237.57 M(+3.0%) |
| Jun 2017 | - | $230.62 M(-0.1%) |
| Mar 2017 | - | $230.94 M(+0.1%) |
| Dec 2016 | $230.73 M(+2.0%) | $230.73 M(+0.1%) |
| Sep 2016 | - | $230.47 M(+2.5%) |
| Jun 2016 | - | $224.88 M(+1.6%) |
| Mar 2016 | - | $221.36 M(-2.1%) |
| Dec 2015 | $226.15 M(-3.2%) | $226.15 M(-1.5%) |
| Sep 2015 | - | $229.52 M(-2.6%) |
| Jun 2015 | - | $235.71 M(+2.1%) |
| Mar 2015 | - | $230.83 M(-1.2%) |
| Dec 2014 | $233.62 M(+324.0%) | $233.62 M(+1.8%) |
| Sep 2014 | - | $229.50 M(+524.3%) |
| Jun 2014 | - | $36.76 M(-9.2%) |
| Mar 2014 | - | $40.47 M(-26.6%) |
| Dec 2013 | $55.10 M(-29.2%) | $55.10 M(-3.1%) |
| Sep 2013 | - | $56.86 M(-5.7%) |
| Jun 2013 | - | $60.30 M(-11.0%) |
| Mar 2013 | - | $67.77 M(-12.9%) |
| Dec 2012 | $77.78 M(-30.8%) | $77.78 M(+2.0%) |
| Sep 2012 | - | $76.27 M(-11.5%) |
| Jun 2012 | - | $86.14 M(-6.9%) |
| Mar 2012 | - | $92.56 M(-17.7%) |
| Dec 2011 | $112.40 M(+39.8%) | $112.40 M(-6.4%) |
| Sep 2011 | - | $120.10 M(-1.6%) |
| Jun 2011 | - | $122.11 M(-5.4%) |
| Mar 2011 | - | $129.14 M(+60.6%) |
| Dec 2010 | $80.41 M(-41.8%) | $80.41 M(-34.1%) |
| Sep 2010 | - | $122.01 M(-2.3%) |
| Jun 2010 | - | $124.94 M(-5.0%) |
| Mar 2010 | - | $131.47 M(-4.8%) |
| Dec 2009 | $138.06 M | $138.06 M(+9.1%) |
| Sep 2009 | - | $126.58 M(-10.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2009 | - | $141.44 M(-8.3%) |
| Mar 2009 | - | $154.28 M(-15.1%) |
| Dec 2008 | $181.81 M(+26.1%) | $181.81 M(+25.2%) |
| Sep 2008 | - | $145.24 M(+3.0%) |
| Jun 2008 | - | $141.00 M(-0.5%) |
| Mar 2008 | - | $141.73 M(-1.7%) |
| Dec 2007 | $144.16 M(-51.7%) | $144.16 M(-22.2%) |
| Sep 2007 | - | $185.23 M(-4.6%) |
| Jun 2007 | - | $194.24 M(-57.3%) |
| Mar 2007 | - | $455.06 M(+52.3%) |
| Dec 2006 | $298.70 M(-29.7%) | $298.70 M(-38.2%) |
| Sep 2006 | - | $483.06 M(-7.9%) |
| Jun 2006 | - | $524.43 M(+2.2%) |
| Mar 2006 | - | $513.05 M(+20.7%) |
| Dec 2005 | $425.04 M(+4.2%) | $425.04 M(+2.6%) |
| Sep 2005 | - | $414.46 M(+2.6%) |
| Jun 2005 | - | $404.11 M(-0.8%) |
| Mar 2005 | - | $407.21 M(-0.1%) |
| Dec 2004 | $407.78 M(+16.0%) | $407.78 M(+64.6%) |
| Sep 2004 | - | $247.70 M(+4.4%) |
| Jun 2004 | - | $237.32 M(+1.5%) |
| Mar 2004 | - | $233.82 M(-33.5%) |
| Dec 2003 | $351.60 M(+74.6%) | $351.60 M(+67.3%) |
| Sep 2003 | - | $210.20 M(+5.2%) |
| Jun 2003 | - | $199.88 M(-1.6%) |
| Mar 2003 | - | $203.15 M(+0.9%) |
| Dec 2002 | $201.41 M(+14.9%) | $201.41 M(+439.1%) |
| Sep 2002 | - | $37.36 M(-8.1%) |
| Jun 2002 | - | $40.65 M(-53.8%) |
| Mar 2002 | - | $87.88 M(-49.9%) |
| Dec 2001 | $175.35 M(+4.0%) | $175.35 M(+3.7%) |
| Sep 2001 | - | $169.14 M(-0.7%) |
| Jun 2001 | - | $170.33 M(+3.6%) |
| Mar 2001 | - | $164.45 M(-2.4%) |
| Dec 2000 | $168.55 M(+5.2%) | $168.55 M(+16.0%) |
| Sep 2000 | - | $145.35 M(-0.3%) |
| Jun 2000 | - | $145.80 M(+2.5%) |
| Mar 2000 | - | $142.20 M(-11.2%) |
| Dec 1999 | $160.20 M(-4.3%) | $160.20 M(-9.3%) |
| Sep 1999 | - | $176.70 M(+15.0%) |
| Jun 1999 | - | $153.60 M(+1.7%) |
| Mar 1999 | - | $151.10 M(-9.7%) |
| Dec 1998 | $167.40 M(+129.0%) | $167.40 M(+41.4%) |
| Sep 1998 | - | $118.40 M(+72.6%) |
| Jun 1998 | - | $68.60 M(+2.8%) |
| Mar 1998 | - | $66.70 M(-8.8%) |
| Dec 1997 | $73.10 M(+8.1%) | $73.10 M(+18.3%) |
| Sep 1997 | - | $61.80 M(-4.5%) |
| Jun 1997 | - | $64.70 M(+1.4%) |
| Mar 1997 | - | $63.80 M(-5.6%) |
| Dec 1996 | $67.60 M(+3.2%) | $67.60 M(+14.4%) |
| Sep 1996 | - | $59.10 M(-7.7%) |
| Jun 1996 | - | $64.00 M(+0.9%) |
| Mar 1996 | - | $63.40 M(-3.2%) |
| Dec 1995 | $65.50 M(+221.1%) | $65.50 M(+8.3%) |
| Sep 1995 | - | $60.50 M(+216.8%) |
| Mar 1995 | - | $19.10 M(-6.4%) |
| Dec 1994 | $20.40 M | $20.40 M(+5.2%) |
| Sep 1994 | - | $19.40 M(+158.7%) |
| Jun 1994 | - | $7.50 M(+2.7%) |
| Mar 1994 | - | $7.30 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual total liabilities?
- What is the all time high annual total liabilities for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual total liabilities year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly total liabilities?
- What is the all time high quarterly total liabilities for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual total liabilities?
The current annual total liabilities of LGND is $86.30 M
What is the all time high annual total liabilities for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual total liabilities is $727.68 M
What is Ligand Pharmaceuticals Incorporated annual total liabilities year-on-year change?
Over the past year, LGND annual total liabilities has changed by -$78.88 M (-47.75%)
What is Ligand Pharmaceuticals Incorporated quarterly total liabilities?
The current quarterly total liabilities of LGND is $113.69 M
What is the all time high quarterly total liabilities for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly total liabilities is $1.41 B
What is Ligand Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?
Over the past year, LGND quarterly total liabilities has changed by +$12.36 M (+12.20%)